CANCER SCI 2019 10.1111/cas.14264
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
Bang1, YJ; Li, CP; Lee, KH; Chiu, CF; Park, JO; Shan, YS; Kim, JS; Chen, JS; Shim, HJ; Rau, KM; Choi, HJ; Oh, DY; Belanger, B; Chen, LT

Front Oncol 2019 10.3389/fonc.2019.01327
Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening
Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J

J CLIN ONCOL 2019 10.1200/JCO.19.00016
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial
Hong1, YS; Kim, SY; Lee, JS; Nam, BH; Kim, KP; Kim, JE; Park, YS; Park, JO; Baek, JY; Kim, TY; Lee, KW; Ahn, JB; Lim, SB; Yu, CS; Kim, JC; Yun, SH; Kim, JH; Park, JH; Park, HC; Jung, KH; Kim, TW

INT J CANCER 2019 10.1002/ijc.32228
Bridging genomics and phenomics of gastric carcinoma
Cho1, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM

TRANSL ONCOL 2019 10.1016/j.tranon.2019.07.017
Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study
Kwon1, D; Kim, B; Shin, HC; Kim, EJ; Ha, SY; Jang, KT; Kim, ST; Lee, J; Kang, WK; Park, JO; Kim, KM

J IMMUNOTHER 2019 10.1097/CJI.0000000000000283
LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target
Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST

CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK

SCI REP-UK 2019 10.1038/s41598-019-51981-5
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C

ANTICANCER RES 2019 10.21873/anticanres.13785
Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer
Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

J Cancer 2019 10.7150/jca.37610
Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY

Transl Cancer Res 2019 10.21037/tcr.2019.09.27
Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

THER ADV MED ONCOL 2019 10.1177/1758835919871126
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
Yoo1, C; Im, HS; Kim, KP; Oh, DY; Lee, KH; Chon, HJ; Kim, JH; Kang, M; Kim, I; Lee, GJ; Oh, SY; Choi, Y; Choi, HJ; Kim, ST; Park, JO; Ryoo, BY

CANCER RES TREAT 2019 10.4143/crt.2018.379
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK

Am J Transl Res 2019
Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification
Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J

CANCER RES TREAT 2019 10.4143/crt.2018.401
Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols
Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K

NEW ENGL J MED 2019 10.1056/NEJMoa1903387
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Golan1, T; Hammel, P; Reni, M; Van Cutsem, E; Macarulla, T; Hall, MJ; Park, JO; Hochhauser, D; Arnold, D; Oh, DY; Reinacher-Schick, A; Tortora, G; Algul, H; O'Reilly, EM; McGuinness, D; Cui, KY; Schlienger, K; Locker, GY; Kindler, HL

J Cancer 2019 10.7150/jca.30355
The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

ANN ONCOL 2019 10.1093/annonc/mdz058
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY

ANN SURG 2019 10.1097/SLA.0000000000002582
Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer
Jang1, JH; Kim, HC; Huh, JW; Park, YA; Cho, YB; Yun, SH; Lee, WY; Yu, JI; Park, HC; Park, YS; Park, JO

TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J